©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Ras Involvement in Signal Transduction by the Serotonin 5-HT2B Receptor (*)

(Received for publication, July 6, 1995; and in revised form, December 4, 1995)

Jean-Marie Launay (3) Guillaume Birraux (3) Dominique Bondoux (3) Jacques Callebert (3) Doo-Sup Choi (1) Sylvain Loric (2) Luc Maroteaux (1)(§)

From the  (1)Institut de Génétique et de Biologie Moléculaire et Cellulaire, Université L. Pasteur de Strasbourg, CNRS, INSERM, BP 163-67404 Illkirch Cedex, France, (2)Différenciation Cellulaire, Unité de Recherche Associée 1960 CNRS, Institut Pasteur, 75724 Paris Cedex 15 France, and (3)Formation de Recherche Associée C. Bernard, Neurochimie des Communications Cellulaires, Service de Biochimie Hôpital Lariboisière, and Laboratoire de Biologie Cellulaire Faculté de Pharmacie rue de l'Observatoire, 75006 Paris, France

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The family of serotonin 5-HT2 receptors stimulates the phospholipase C second messenger pathway via the alpha subunit of the G(q) GTP-binding protein. Here, we show that agonist stimulation of the 5-HT2B receptor subtype stably expressed in the mouse fibroblast LMTK cell line causes a rapid and transient activation of the proto-oncogene product p21 as measured by an increase in GTP-bound Ras in response to serotonin. Furthermore, 5-HT2B receptor stimulation activates p42/p44 (ERK2/ERK1) mitogen-activated protein kinases as assayed by phosphorylation of myelin basic protein. Antibodies against p21, Galpha(q), -beta, or -(2) subunits of the GTP-binding protein inhibit MAP kinase-dependent phosphorylation. The MAP kinase activation is correlated with a stimulation of cell division by serotonin. In addition to this mitogenic action, transforming activity of serotonin is mediated by the 5-HT2B receptor since its expression in LMTK cells is absolutely required for foci formation and for these foci to form tumors in nude mice. Finally, we detected expression of the 5-HT2B receptor in spontaneous human and Mastomys natalensis carcinoid tumors and, similar to the 5-HT2B receptor transfected cells, the Mastomys tumor cells are also responsive to serotonin with similar coupling to p21 activation.


INTRODUCTION

Serotonin (5-hydroxytryptamine, 5-HT) (^1)is one of the best known examples of a neurotransmitter that mediates a wide variety of physiological effects, including peripheral and central actions, through the binding to multiple receptor subtypes(1) . The major sites of 5-HT synthesis and storage are located in the periphery, in gut enterochromaffin cells and blood platelets, respectively. The large diversity of 5-HT functions is paralleled by the pharmacological complexity of 5-HT receptors. At least four classes of 5-HT receptors have been distinguished pharmacologically, reflecting the second messenger system to which the receptor is coupled. The family including 5-HT1 and 5-HT5 subtypes of receptors interacts negatively with adenylyl cyclase, the 5-HT2 subfamily of receptors is coupled to the activation of the phospholipase C-beta, the 5-HT3 receptor is a ligand-gated ion channel, and the family, including 5-HT4, 5-HT6, and 5-HT7 subtypes of receptors, activates adenylyl cyclase(2) .

5-HT2 receptors mediate many of the central and peripheral physiological functions of 5-HT. Cardiovascular effects include contraction of blood vessels and shape change in platelets; central nervous system effects include neuronal sensitization to tactile stimuli and mediation of hallucinogenic effects of lysergic acid diethylamide and related phenylisopropylamine hallucinogens. The most characterized 5-HT2 receptor subtypes are the 5-HT2A (formerly 5-HT2) and the 5-HT2C (formerly 5-HT1C) both of which stimulate phospholipase C-beta. Many investigators have observed that some peripheral 5-HT2-like effects of 5-HT are mediated by ``atypical'' receptors(3) . In the mouse, we cloned a new member (5-HT2B) of the 5-HT2 family which is mainly expressed in the cardiovascular system, gut, and developing brain(4) . This mouse 5-HT2B receptor shares the highest degree of homology with the other 5-HT2B receptors cloned from the rat fundus (5, 6) and, more recently, from human libraries (7, 8, 9) (for review, see (10) ) and from Drosophila(11) .

5-HT, detected early in embryonic development(12) , participates in craniofacial (13) and cardiovascular morphogenesis (14, 15) by unknown molecular mechanisms. We have investigated the growth factor properties mediated by the 5-HT2B receptor since (i) both Drosophila 5-HT2 and mouse 5-HT2B receptors are expressed during embryogenesis (11, 16) , (ii) the mitogenic activity of 5-HT has been linked mainly to 5-HT2 receptor-dependent stimulation of phospholipase C-beta/protein kinase C; when expressed at high density in NIH3T3 fibroblasts, both 5-HT2C and 5-HT2A have mitogenic effects induced by 5-HT(17, 18) . In mammalian cells, the ability to activate the mitogen-activated protein (MAP) kinase cascade is a feature common to many extracellular stimuli, including growth factors, hormones, and neurotransmitters, leading to transcription factor phosphorylation and to cell division(19) . The signaling pathways that activate the MAP kinase cascade use receptor tyrosine kinase or non-receptor tyrosine kinases. Other stimuli activate GTP-binding protein (G-protein)-coupled receptors generating second messengers or activating ion channels (20) .

The present report concerns studies on the mitogenic and transforming activity of the mouse 5-HT2B receptor. This receptor mediates 5-HT stimulation of MAP kinase through the Ras pathway and can be classified as ligand-dependent proto-oncogene since expression of the 5-HT2B receptor is necessary and sufficient to induce tumor formation in nude mice. In addition, expression of the 5-HT2B receptor is detected in vivo in spontaneous human and Mastomys natalensis carcinoid tumors (CT).


EXPERIMENTAL PROCEDURES

Materials

Ketanserin, ritanserin, and setoperone were kindly provided by Janssen (Beerse, Belgium). ICS 205-930 and MDL 72222 were gifts from Sandoz (Switzerland) and Merell-Dow (Strasbourg, France), respectively. Other neurochemicals were from RBI (Natick, MA). All other chemicals were reagent grade, purchased from commercial sources. The radioactive compound (±)-[I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl ([I]DOI, 81.4 TBq/mmol) was purchased from DuPont NEN. Dulbecco's modified Eagle's medium (DMEM) and fetal calf serum (FCS) were from Life Technologies, Inc.

All antibodies are from Santa Cruz Biotechnology (dilution 1/1000) and include a rat monoclonal antibody against v-Ha-Ras (259) which also recognizes Ki- and N-Ras p21, rabbit antiserum against the amino-terminal sequence of mouse Galpha(q)/11 (E17), rabbit polyclonal antibody against the carboxyl terminus of MAP kinase-p44 (C16) which also reacts with p42, rabbit antiserum against the amino-terminal sequence of bovine G2 (A16), and rabbit polyclonal antibody against the carboxyl terminus of mouse Gbeta1 (T20) which also reacts with Gbeta1,-2,-3,-4.

Transfection and Stable Expression of the 5-HT2B Mouse Receptor

For this study, the previously described LM5 (21) clone is used. It expresses 224 ± 8 fmol of 5-HT2B receptor/mg of protein, as measured by [I]DOI binding experiments. Parental LMTK and transfected LM5 cells were grown in DMEM containing 10% 5-HT-depleted FCS prepared as described. (^2)

Determination of GTPase Activities

Whole cell GTPase activity was measured on cell extracts prepared after incubation in the presence of 1 µM 5-HT as described in (21) and (22) by monitoring the release of [P]P(i) from [-P]GTP. Membranes were prepared as described in (21) , incubated for 2 min at 20 °C, mixed with 0.15 µM [-P]GTP, and then incubated for an additional 3 min. The reaction was terminated by adding 500 µl of cold 50 mM KH(2)PO(4) buffer, pH 7.40, containing 5% (w/v) Norit-A charcoal, and the supernatant was taken for scintillation counting. Reactions were performed in quadruplicate with blanks containing no added membranes. [P]P(i) released from [-P]GTP in the absence of membranes represented 0.7 to 2% of the added [-P]GTP. GTPase activity is expressed as femtomoles of GTP hydrolyzed per mg of protein per min.

Data Analysis and Statistics

Binding data were analyzed using the iterative nonlinear fitting software LIGAND 3.0(23) . This allows calculation of dissociation constants in saturation experiments (K(d)). Data points were tested (F-test) to fit a single- or two-site model with or without an additional parameter regarded as nonspecific binding. The statistical analysis on small groups were performed by nonparametric tests(24) . The chosen significance criterion was p < 0.05. All values are given as arithmetic means ± S.E. of the indicated number of experiments.

Cellular Division Assay

Cells were plated at an initial density of 10^5 cells/35-mm dish, in DMEM containing 10% 5-HT-free FCS. After 24 h, the medium was replaced with DMEM containing 0.6% 5-HT-free FCS, in the presence or absence of serotonergic drugs as indicated. The medium was changed every 2 days. After 5 and 8 days, cells were detached from dishes with trypsin (1:250) and counted twice.

Focus Formation Assay

Cells were grown in 25-cm^2 flasks with 10% FCS until confluency. After incubation for 2 or 3 weeks in medium containing 3% 5-HT-free FCS with or without 1 µM 5-HT or 0.1 µM DOI and/or 1 µM ritanserin, foci were scored. The medium was changed every 2 days. In some instances, foci were isolated and expanded in DMEM containing 10% 5-HT-free FCS and the initial inducer (1 µM 5-HT or 0.1 µM DOI).

Tumor Formation in Nude Mice

Cells were nonenzymatically removed from culture dishes, washed with PBS, and injected subcutaneously into nu/nu CD1 mice (Charles River) at two locations with approximately 10^6 cells per 0.1 ml at each site.Tumor cell lines were established by plating dissociated cells in DMEM containing 10% FCS(25) .

Ras Activation Assay

Activation of Ras was determined by analyzing the ratio of GTP- versus GDP-bound to immunoprecipitated Ras from control and stimulated cells(26) . Briefly, cells were incubated with 30 µCi/ml [P(i)] for 6 h and then stimulated. Cell lysates were prepared, Ras was immunoprecipitated, and the bound [P]-GTP and [P]-GDP was resolved using PEI-cellulose thin-layer chromatography. Quantitation of radiolabeled GDP and GTP was accomplished using an automated LB 2832 radioactivity scanner (Berthold, Wilbad, Germany). Control refers to immunoprecipitations performed in the absence of primary anti-Ras antibody.

Assay of MAP Kinase Activity

Cells (4 times 10^6 per 100-mm plate) were incubated for 20 h in DMEM without serum but with 0.1% bovine serum albumin to achieve quiescence. Cells were then collected and MAP kinase activity was measured essentially as described (27) . Cells were rinsed three times and harvested by scraping in ice-cold phosphate-buffered saline. Cell lysis was accomplished in 50 mM beta-glycerophosphate (pH 7.20), 100 µM sodium vanadate, 2 mM MgCl(2), 1 mM EGTA, 0.5% Triton X-100, 10 µg/ml leupeptin, 0.02 unit/ml aprotinin, and 1 mM dithiothreitol. Cell lysate supernatants were collected after microcentrifugation for 10 min at 4 °C (removing insoluble cell components), normalized for protein using the bicinchoninic acid assay, and 0.5 ml of each sample was loaded onto Mono Q columns of a fast protein liquid chromatography system equilibrated in 50 mM beta-glycerophosphate (pH 7.20), 100 µM sodium vanadate, 1 mM EGTA, and 1 mM dithiothreitol. Proteins were eluted with a linear gradient of NaCl (0-0.4 M) and collected in 1-ml fractions. Twenty µl of each fraction were assayed for kinase activity in reaction buffer containing 1 mCi of [-P]ATP, 20 µM ATP, and 1.5 mg/ml myelin basic protein (MBP) (Sigma) for 20 min at 30 °C, essentially as described(28) .

5-HT2B Antiserum

Mouse 5-HT2B receptor carboxyl terminus synthetic peptide was used for rabbit immunization according to Fisher et al.(29) . The peptide has the following sequence, CSTIQSSSIILLDTLLTENDGDKAEEQVSYI, and has no homology with other known 5-HT receptors. Antibodies were affinity-purified and tested as described(30) . The specificity was assayed by immunostaining of the cells transfected by 5-HT receptor cDNA (5-HT1A, -1B, -2A, -2B, or -2C) and by Western blotting of their protein extracts (final concentration 0.2-2 µg/ml). The 5-HT2B-transfected cells show immunoreactivity which is abolished by preincubation of the serum with an excess of the immunizing peptide, and the protein extract reveals one single protein band of the right size on Western blot. In addition, this serum recognizes the mouse, Mastomys, and human 5-HT2B receptor protein.


RESULTS

GTPase Activation

We have previously shown (21) that the mouse 5-HT2B receptor, stably expressed in fibroblast LMTK cells (LM5), induces GTPase activation and inositol 1,4,5-trisphosphate production when stimulated by agonist, whereas the parental LMTK cells are unresponsive. This activity is blocked by antibodies against Galpha(q)/11, but not by pertussis or cholera toxins or by anti-Galpha(i) or anti-Galpha(s) antibodies, indicating that it is mediated by the G-protein, Galpha(q)/11, but not by G(s) or G(i)(21) . A more detailed examination of the GTPase activity in LM5 cells induced by 5-HT reveals a first activation at 1.5 min followed by a second activation peaking at 5 min, whereas the LMTK cells are unresponsive (Fig. 1A). Therefore, we investigated the possibility of other coupling mechanisms for the 5-HT2B receptor. Interestingly, the early phase of GTPase activation (at 1.5 min after 5-HT addition) can almost completely be blocked by incubation in the presence of anti-Galpha(q), -beta, or -(2) subunit antibodies, without affecting the LMTK cells (Fig. 1C). In contrast, at 5 min after 5-HT addition, more than 95% of the GTPase activation is resistant to treatment by anti-Galpha(q) antibody, but about 35% of the activity is sensitive to treatment by anti-beta or -(2) subunit antibodies and by Ras antibodies, without affecting the LMTK cells (Fig. 1D). This suggests that the small G-protein Ras participates, at least partially, at the late phase of GTPase activation.


Figure 1: 5-HT induced GTPase activation. A, kinetics of GTPase activation by 5-HT, the whole-cell GTPase activity was measured as described in (21) and (22) by monitoring the release of [P]P(i) from [-P]GTP in response to 5-HT activation. GTPase activity is expressed as femtomoles of GTP hydrolyzed per mg of protein per min. Time starts with 5-HT addition. 5-HT (10 nM) stimulations of LMTK () or of LM5 (box) cells have been obtained in four independent experiments. The 5-HT-induced LM5 curve presents peaks at 1.5 min and at 5 min. B, kinetics of Ras activation in response to 5-HT, the activation of Ras-GTPase activity was determined by analyzing the ratios of GTP to GDP bound to immunoprecipitated Ras from control and stimulated cells; the bound [P]GTP and [P]GDP were resolved using polyethyleneimine-cellulose thin layer chromatography and quantitation of radiolabeled GDP and GTP. 5-HT (10 nM) stimulations of LMTK () or of LM5 (box) cells or of LM5 cells in the presence of 1 nM ritanserin (x) have been performed four times independently. The LM5 cells present a peak at 5 min after 5-HT addition. The left scale is the amount of GTP-bound Ras as the percentage of GTP plus GDP-bound Ras, and the right scale is the same values converted in GTPase activity expressed as percentage of the maximal total GTPase activity of Fig. 1A. C and D, the cellular level of GTPase activity was investigated on LMTK (white boxes) or LM5 (gray boxes) cells without treatment (circle) or after incubation with 5-HT alone (box), 5-HT plus anti-Ras antibodies (), 5-HT plus anti-Galpha(q) antibodies (diamond divided lengthwise), 5-HT plus anti-beta antibodies (up triangle), 5-HT plus anti- antibodies (down triangle), 5-HT plus anti-beta and - antibodies (diamond divided widthwise). The experiments have been performed four times. Specific antibodies were used at a final concentration of 2 ng/ml which is within the range of the physiological concentrations of total IgG (around 10 mg/ml serum). The incubation in the same conditions with preimmune serum was ineffective (not shown). C, blocking of the 5-HT-induced GTPase activation at 5 min. D, blocking of the 5-HT-induced GTPase activation at 10 min.



In several signaling paradigms thought to involve the function of the Ras protein, stimulation with growth factors leads to the rapid accumulation of Ras protein in its GTP-bound (i.e. active) state. The immunoprecipitation by anti-Ras antibodies of extracts of LM5 cells indicates that stimulation by 5-HT, transiently and specifically, increases the amount of the GTP-bound Ras complex (Fig. 1B). This activity is not seen in the parental cell line nor in presence of the antagonist ritanserin. Interestingly, the LM5 cell basal level of Ras GTPase activity is more than three times higher than that of LMTK cells. Compared to basal levels of LM5 cells, the increase in GTP-bound Ras induced by 5-HT is nearly 4-fold at 5 min, 78.2% ± 4.3 (n = 4) of which is sensitive to beta antibodies (not shown). By 30 min after agonist addition, GTP-bound Ras returns to basal levels.

5-HT Action on Cell Division

The activation of Ras, known to stimulate cell division, has been investigated further by measuring phosphorylation by MAP kinase of MBP: 5-HT stimulation of LM5 cells induces MAP kinase activation (Fig. 2A) which is not seen in the presence of ritanserin. At 10 min, this 5-HT stimulation, not observed in LMTK cells, is almost completely blocked by ritanserin, a 5-HT2 antagonist, or by incubation in the presence of antibodies against the Ras, beta, -(2), or Galpha(q)/11 subunit (Fig. 2B).


Figure 2: 5-HT-induced MAP kinase activity. MAP kinase activity was measured on quiescent cells extracts by purification onto Mono Q columns in four independent experiments. A, kinetics of MAP kinase activation, MBP phosphorylation levels were essayed in duplicate using protein extracts obtained at various times after 5-HT addition to quiescent LM5 (box) cells alone or in the presence of 1 nM ritanserin (x). The 5-HT-induced LM5 cell curve presents a peak at 10 min. B, blocking of MAP kinase activity at 10 min, the cellular level of MAP kinase activity was investigated on LMTK (white boxes) or LM5 (gray boxes) cells after 10 min without treatment (circle) or after a 10-min incubation with 5-HT alone (box), 5-HT plus ritanserin (x), 5-HT plus anti-Galpha(q) antibodies (diamond divided lengthwise), 5-HT plus anti-beta and - antibodies (diamond divided widthwise), or 5-HT plus anti-Ras antibodies (). The blockers of the GTPase activity also block the MAP kinase activity.



Since stimulation of MAP kinases can lead to cell division(31) , we investigated further the effect of 5-HT on the rate of LM5 cell division. This analysis indicates that 5-HT acts through the 5-HT2B receptor on the steady state number of cells: both 5-HT2 agonists 5-HT (1 µM) and DOI (0.1 µM) stimulate cell growth of the LM5 clone (but not of the LMTK cells). These effects can be inhibited by incubation of agonists together with 1 µM ritanserin (Fig. 3A). Interestingly, in the absence of agonist and in 5-HT-free serum, the LM5 cells have a cell division rate that is 2-fold greater than the LMTK cells, and this rate is reduced by the antagonist ritanserin alone (Fig. 3A).


Figure 3: Mitogenic action of 5-HT. No treatment (circle) or treatment in the presence of 1 nM ritanserin (+), 1 nM DOI (), 10 nM 5-HT (box), 1 nM DOI plus 1 nM ritanserin (), or 10 nM 5-HT plus 1 nM ritanserin (x) of LMTK (white boxes) or of LM5 (gray boxes) cells were used to assess the effect on cell growth or on foci formation. A, cellular division assay, cells plated at an initial density of 10^5 cells/35-mm dish, in 10% 5-HT-free FCS medium, and transferred after 24 h to medium containing 0.6% 5-HT-free FCS, with or without serotonergic drugs as indicated, were counted after 5 days. Each sample of four independent experiments was counted twice. Stars indicate statistically significant differences. The results are expressed as the fold increase in cell per day. The unstimulated LM5 cells have about twice the cell division rate of the parental LMTK cells, ritanserin alone inhibits the LM5 cells division rate, whereas agonists stimulate this rate. B, focus formation assay, foci were scored on confluent cells after 2 or 3 weeks in medium containing 3% 5-HT-free FCS with or without serotonergic drugs as indicated in 4 independent experiments. Spontaneous foci appear in LM5 cells, but agonists enhance the number of foci.



Focus Formation and Tumor Induction in Nude Mice

The long-term effect of the 5-HT2B receptor on the growth properties of the LM5 cells was also investigated: LM5 cells were grown to confluence, and the loss of contact inhibition was scored by counting the number of foci formed after 2 weeks or longer. The control cells (nontransfected LMTK cells) never generated foci in 3% 5-HT-free FCS, with or without addition of 5-HT, DOI, or ritanserin. In contrast, in the absence of 5-HT2B agonists in the medium, foci occurred in LM5 cells, although at a frequency 10 to 25 times lower than that observed in agonist-treated cells (Fig. 3B and Table 1). To determine whether the 5-HT2B receptor-expressing cells were transformed, tumorigenicity was assessed by subcutaneous injection into nude mice. No tumors were observed upon injection of control LMTK cells. In contrast, tumors appeared in all LM5-injected mice within 4 weeks. Similar results were observed when 10^6 foci-derived cells from agonist-stimulated or from nonstimulated LM5 cells were injected separately into nude mice. Tumors were observed in every case, but tumors formed by foci-derived cells appeared earlier (2-3 weeks) and never spontaneously regressed.



We then investigated receptor expression in tumors by examining the presence of 5-HT2B-specific binding on tumor-derived cell lines. Interestingly, 2 weeks of treatment of nude mice-bearing tumors with the antagonist ritanserin induces a significant reduction in tumor size, suggesting the presence of the 5-HT2-like receptors on these tumors (Table 1). DOI binding under nonsaturating conditions (2 nM [I]DOI) indicates a relative value of receptor densities. We, therefore, examined the persistence of the 5-HT2B receptor expression by plating the tumor-derived cells and estimating the receptor density from the DOI binding values. All tumor-derived cell lines expressed a significantly (p < 0.01, KS test) greater density of 5-HT2B receptors than the parental LM5 cell line (Table 1). This suggests that the growth of these tumors is associated with selective expansion of cells which express the highest number of 5-HT2B receptors (Table 1). Furthermore, all cell lines derived from tumors retain the ability to form foci, with a rough correlation between the number of foci and the density of 5-HT2B receptors (Table 1). To test whether the formation of foci requires activation of 5-HT2B receptors, tumor-derived cell lines were plated on a lawn of LMTK cells in the presence or absence of antagonists, ritanserin, or mesulergine for 2 weeks. As for the parental foci, the ability of the tumor-derived cell lines to form foci appears almost (95%) completely blocked by antagonists (Table 1). Thus, foci formation by these tumor-derived cells remain ligand-dependent.

In Vivo Localization of 5-HT2B Receptor in Tumors

The observation that 5-HT2B receptor expression is tumorigenic for LMTK cells raises the question of its physiological relevance. Since the 5-HT2B receptor is expressed in several peripheral tissues, we looked at its expression in peripheral tissue-derived tumors. Most of the human tumors derived from the enterochromaffin cell, carcinoid tumors (CT), have the property of synthesizing high amounts of 5-HT(32) . An animal model of spontaneous appearing CT has been described in the aged M. natalensis (muridae) bearing spontaneous, malignant CT, originally described in (33) and homotransplanted to syngenic animals by Hosoda et al.(34) . Antibodies, raised against the carboxyl-terminal portion of the mouse 5-HT2B receptor, which are specific for 5-HT2B receptors, were used on tissue sections from human CT and Mastomys E-line CT (mainly 5-HT-secreting(25, 35) ). Positive cells are organized in neuroendocrine-like structures (Fig. 4, A and B) in all examined human and Mastomys CT samples, whereas, in LM5-derived nude mice tumor, 5-HT2B receptors are present in fibrosarcoma-like structures (Fig. 4D). Therefore, in vivo, the 5-HT2B receptor is also expressed in spontaneously occurring malignant tumors.


Figure 4: Immunohistochemistry of anti-5-HT2B receptor antibody on tissue sections. Tissue sections were incubated in the presence of anti 5-HT2B receptor antibodies and revealed by secondary antibodies coupled to peroxidase. Similar experiments performed after incubation of the serum with the immunizing peptide reveals no signal. The original magnifications were times 200. A, human CT section treated with anti-5-HT2B antibodies, neuroendocrine-like structure expressing the 5-HT2B receptor protein are surrounded by normal tissue. Similar 5-HT2B positive staining has been observed in three out of three independent human tumor samples. B, Mastomys CT section treated with anti 5-HT2B antibodies, similar structures are observed in all samples examined. C, normal nude mice tissue section treated with anti 5-HT2B antibodies, no 5-HT2B receptor expression can be detected. D, nude mice tumor section treated with anti-5-HT2B antibodies, 5-HT2B receptors are seen in the four observed tumors and present a fibrosarcoma-like tumor organization.



5-HT Stimulates Ras Activity in Mastomys CT

After plating dissociated Mastomys CT cells, we investigated their response to 5-HT stimulation. As shown on Fig. 5, immunoprecipitation of tumor cell extracts with anti-Ras antibodies indicates that 5-HT induces an activation of the Ras-GTPase activity in a manner similar to that observed in LM5 cells, stimulation which is blocked by the antagonist ritanserin. However, the level of Ras stimulation by 5-HT is only 2.2 times the basal level which is high, probably due to endogenous Ras activity in these tumor cells (Fig. 5).


Figure 5: Ras activation in Mastomys CT by 5-HT. The Ras-GTPase activity was determined by analyzing the amount of GTP and GDP bound to immunoprecipitated Ras from control and stimulated cells as in Fig. 1B. Stimulation of LMTK (white boxes), of LM5 (gray boxes), or of Mastomys dissociated CT cells (black boxes) alone (circle) or in the presence of 10 nM 5-HT (box) or of 10 nM 5-HT plus 1 nM ritanserin (x) have been performed 4 times. The results, after 5 min of stimulation (peak of Fig. 1B), are expressed as femtomoles of GTP bound per mg of protein per min. The LMTK cells are not responsive to 5-HT, in LM5 cells as in Fig. 1B, the amount of GTP-bound Ras is stimulated 4 times by 5-HT and blocked by ritanserin, whereas in the Mastomys tumor cells the amount of GTP-bound Ras is stimulated 2.2 times and is also blocked by ritanserin. We notice that the level of active Ras in the Mastomys tumor cells is nearly as high as that of stimulated LM5 cells, indicating that Ras is already activated in these tumor cells.




DISCUSSION

The aim of this study is to characterize further biochemical signals transduced by 5-HT in 5-HT2B receptor transfected cells (LM5). The early GTPase activation involves Galpha(q), -beta, and -(2) subunits (1.5 min) (Fig. 1, A-D). The late phase of GTPase activation (5 min) is resistant to anti-Galpha(q) antibodies and, therefore, implicates secondary activation of other G-proteins: 35% of this late GTPase is sensitive to anti-Ras and to anti-beta antibodies (Fig. 1, A, C, and D). In addition, 5-HT2B agonists stimulate the accumulation of the GTP-bound form of Ras with similar kinetics peaking at 5 min after 5-HT stimulation (Fig. 1B). These results suggest that Ras is involved in the secondary phase of GTPase activation and that the beta subunit is mediating this effect. The amount of GTP-bound Ras is stimulated 4-fold by 5-HT, and this is blocked in the presence of ritanserin (Fig. 1B). However, the Ras-GTPase activity determined by immunoprecipitation of Ras (Fig. 1B and Fig. 5) represents only 18% of the maximal total cellular GTPase activity (Fig. 1A), which in turn corresponds to approximately half of the GTPase activity blocked by anti-Ras antibodies (Fig. 1D). This indicates that other processes, that are inhibited by anti-Ras antibodies, may also participate in the 5-HT2B-dependent GTPase stimulation. Agonist stimulation of heterotrimeric G-proteins involves dissociation of the Galphabeta subunit from the receptor(36) . The beta subunit, subsequently released from Galpha(q)(37, 38) , stimulates the Ras-GTPase activity, raising, at least in part, the late GTPase activity. The Ras stimulation by the beta subunit remains to be dissected out. Candidates to mediate this stimulation are proteins containing plekstrin homology domain since beta subunits have affinity for such domains at the carboxyl terminus of beta-adrenergic kinase(39) . This includes the GTPase activating proteins, whose noncatalytic domain has been reported to interfere with transformation induced by G-protein-coupled receptors (40, 41) or other protein kinases (see (42) for review).

In LM5 cells, 5-HT triggers the activation of p42/p44 (ERK2/ERK1) MAP kinase cascade (Fig. 2A). This ``extracellular signal-regulated kinase'' pathway is classically used by growth factor stimulation of intracellular tyrosine kinase activity(43) . This cascade leads to cell division(31) , differentiation, and/or transformation and can be potentiated by stimulation of Galpha(q)(44) . Ligands for multiple G-protein coupled receptors have been shown to stimulate tyrosine kinase activity(42, 45, 46, 47) , and angiotensin II AT1 receptor recently has been reported to stimulate directly the Jak/STAT pathway in rat aortic smooth muscle(48) . The contribution of the 5-HT2B receptor to tyrosine kinase activation remains to be investigated. However, MAP kinase activity has been reported to be stimulated by G(i), a pertussis toxin-sensitive G-protein(47, 49) , and by G(q)(50, 51, 52) or inhibited by G(s) (see (53) for review). Furthermore, 90% of the 5-HT-induced MAP kinase activation in LM5 cells is specifically blocked by antibodies against either Galpha(q), -beta, -(2) subunit or Ras (Fig. 2B), also suggesting that the dissociation of the Galpha(q) and -beta as well as Ras activation are involved in this stimulation. In contrast to other receptor systems(52, 54, 55, 56, 57) , the contribution of the phospholipase C-beta stimulation to MAP kinase activation seems only minor. Nevertheless, our results add 5-HT via the 5-HT2B receptors to the growing list of receptors, including alpha(1)-adrenergic, bombesin, m1-5 acetylcholine muscarinic, prostaglandin, and thrombin, which activate Ras by Galpha(q)(58, 59, 60) or MAP kinases by Galpha(q) and -beta subunit(51, 52) .

The stimulation of the 5-HT2B receptor not only triggers the MAP kinase cascade, but also activates the LM5 cell division rate (Fig. 3A). This is confirmed by the enhancement of [^3H]thymidine incorporation in response to agonists (data not shown). Therefore, these data demonstrate that 5-HT has a mitogenic effect on LM5 cells. This mitogenic effect probably results from MAP kinase stimulation via Ras, Galpha(q), and -beta, as already shown in other systems by use of the dominant negative form of Ras (58) or of constitutively active G(q)(44, 61) . In addition to short-term effects, MAP kinase activation may lead to long-term effects, including cell transformation and/or differentiation. LM5 cells grown to confluence are forming foci, an effect which is stimulated by agonist and inhibited by antagonist (Fig. 3B). Surprisingly, the potency of antagonist is greater with regard to the ability to inhibit foci formation than with the rate of cell division (Fig. 3, A and B). This difference may be related to different responses in different physiological states (exponential growth versus quiescent) and probably corresponds to short-term effects versus long-term effects involving different effectors of the receptor. In addition, all nude mice-derived tumor cells express more 5-HT2B binding sites than LM5 cells. This indicates that a threshold level of receptor expression (1 pmol/mg of protein) is probably necessary for transformation. However, these events remain 5-HT and 5-HT2B receptor-dependent (Table 1). Although the contribution of Ras stimulation to the long-term alterations is probable, since activated Ras is known to transform NIH3T3 fibroblasts (62) and since expression of a dominant negative form of Ras inhibits the muscarinic m5 receptor-dependent transformation(60) , additional transduction mechanisms are probably involved. Nevertheless, expression of the 5-HT2B receptor triggers both the 5-HT-mediated mitogenicity and the transformed phenotype of the LMTK cells, indicating that the 5-HT2B receptor behaves as a ligand-dependent proto-oncogene for the LMTK cell line.

Interestingly, the unstimulated LM5 cells have a higher cell division rate than the parental LMTK cells. This basal activity is partially reduced in the presence of the antagonist ritanserin (Fig. 3A) (inverse agonist) and probably corresponds to an intrinsic activity of the receptor which has also been shown for the 5-HT2C receptor(63) . Similarly, in unstimulated LM5 cells, foci spontaneously appear and the basal level of Ras activity is elevated suggesting intrinsic activity of the 5-HT2B receptor. Therefore, intrinsic activity and a high level of expression may be two important parameters for tumor development. Tumor regression in nude mice induced by ritanserin treatment may open lines of investigation to develop new types of therapeutic agents.

In several aspects, the oncogenic properties of the 5-HT2B receptor seems to differ from those described for the other 5-HT2 receptors: very high levels of 5-HT2A-2C receptor expression are required in NIH3T3 cells to induce foci formation (>10 pmol of receptor/mg of protein), cells derived from nude mice tumors induced by these foci are 5-HT independent(17, 18) , and expression of the 5-HT2C receptor does not transform the CCL39 cell line(64) . Several factors may be responsible for these differences. (i) Use of 5-HT-depleted serum (<1 nM 5-HT) in this report may be important for the full activity of the receptor. (ii) The different cell lines (LMTK, NIH3T3, or CCL39) may express different levels of G-proteins (65) or different combinations of G-protein subunits(66) , some of which may be crucial for transformation; the (2) subunit has also been implicated in G(q)-mediated Ras activation(51) . (iii) Despite common coupling to phospholipase C-beta, the ability to stimulate Ras has not been reported for the 5-HT2A or 5-HT2C receptors. (iv) The carboxyl-terminal region of the third intracellular loop, close to the sixth transmembrane domain, contains important amino acids involved in coupling to different G(q) subtypes of G-protein (67) and is not conserved among 5-HT2 receptors. This region controls the G(q)-dependent mitogenicity of the m1-5 muscarinic receptors (65) and, when mutated, leads to constitutive activation of the Galpha(q) by the alpha-adrenergic receptor(68) .

Furthermore, 5-HT which is present early in embryonic development (12) participates in craniofacial (13) and cardiovascular morphogenesis(14, 15) . Therefore, some 5-HT trophic functions during embryogenesis may be controlled by the mitogenic and transforming properties of 5-HT2B receptor. Its embryonic expression starts earlier than the 5-HT2A or 5-HT2C receptors (69) and is located in heart primordia and in neural fold before neural tube closure(4, 16) . In addition, the 5-HT2B receptor, which is expressed by immortalized teratocarcinoma-derived cells 1C11 before complete serotonergic cAMP-induced differentiation(^3)(21) , seems to have an autocrine function.^2

Finally, the 5-HT2B receptor is expressed in tumors from both human and M. natalensis species (Fig. 4, B and C). The Mastomys CT expresses a 5-HT2B receptor very similar to the mouse receptor, (^4)and the human 5-HT2B receptor cDNA has been found in a cDNA library made from mRNA of a human CT(16) . In addition, the pharmacology of the Mastomys CT indicates a high level of 5-HT2B receptor expression.^4 Therefore, this report makes, for the first time, a parallel between induced tumorigenicity by expression of the 5-HT2B receptor in nontransformed fibroblasts and its expression by spontaneous tumors, which are both coupled to Ras activation (Fig. 5). However, the participation of the 5-HT2B receptor in enterochromaffin cell malignant transformation remains to be proven.


FOOTNOTES

*
This work was supported by funds from the CNRS, the INSERM, the Centre Hospitalier Universitaire Régional, and by grants from the European Economic Community, the Ministère de l'Enseigement, the Fondation pour la Recherche Médicale, and Association pour la Recherche contre le Cancer Grant 6800 (to D.-S. C. and L. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Institut de Génétique et de Biologie Moléculaire et Cellulaire CNRS, INSERM, Université L. Pasteur de Strasbourg BP 163-67404 Illkirch Cedex, France. Tel: 33-88-65-33-85; Fax: 33-88-65-32-01.

(^1)
The abbreviations used are: 5-HT, serotonin, 5-hydroxytryptamine; CT, carcinoid tumors; DMEM, Dulbecco's modified Eagle's medium; [I]DOI, (±)-[I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl; FCS, fetal calf serum; G-protein, GTP-binding protein; MAP, mitogen-activated protein; MBP, myelin basic protein.

(^2)
J.-M. Launay, S. Loric, V. Bastide-Douzou, M. Da Prada, and O. Kellermann, submitted for publication.

(^3)
O. Kellermann, S. Loric, L. Maroteaux, and J.-M. Launay, submitted for publication.

(^4)
J.-M. Launay and L. Maroteaux, unpublished data.


ACKNOWLEDGEMENTS

We wish to acknowledge P. Hickel and D. Prulière, for excellent technical assistance, M. Acker and B. Heller, for help in tissue culture cells, A. Staub and F. Ruffenach for oligonucleotide synthesis, S. Vicaire for DNA sequencing, and B. Boulay and J.-M. Lafontaine for help in preparing the artwork of this manuscript. We thank Dr. C. Tamai for critical reading and English correction of the manuscript and Dr. E. Borrelli for helpful discussions.


REFERENCES

  1. Wilkinson, L. O., and Dourish, C. T. (1991) in Serotonin Receptor Subtypes: Basic and Clinical Aspects (Peroutka, S. J., eds) Vol. 15, pp. 147-210, Wiley-Liss, New York
  2. Peroutka, S. J. (1995) Trends Neurosci. 18, 68-69 [CrossRef][Medline] [Order article via Infotrieve]
  3. Saxena, P. R., and Villalon, C. (1991) Trends Pharmacol. Sci. 12, 223-227 [CrossRef][Medline] [Order article via Infotrieve]
  4. Loric, S., Launay, J.-M., Colas, J.-F., and Maroteaux, L. (1992) FEBS Lett. 312, 203-207 [CrossRef][Medline] [Order article via Infotrieve]
  5. Foguet, M., Hoyer, D., Pardo, L. A., Parekh, A., Kluxen, F. W., Kalkman, H. O., Stühmer, W., and Lübbert, H. (1992) EMBO J. 11, 3481-3487 [Abstract]
  6. Kursar, J. D., Nelson, D. L., Wainscott, D. B., Cohen, M. L., and Baez, M. (1992) Mol. Pharmacol. 42, 549-557 [Abstract]
  7. Choi D.-S., Birraux, G., Launay, J.-M., and Maroteaux, L. (1994) FEBS Lett. 352, 393-399 [CrossRef][Medline] [Order article via Infotrieve]
  8. Kursar, J. D., Nelson, D. L., Wainscott, D., and Baez, M. (1994) Mol. Pharmacol. 46, 227-234 [Abstract]
  9. Schmuck, K., Ullmer, C., Engels, P., and Lübbert, H. (1994) FEBS Lett. 342, 85-90 [CrossRef][Medline] [Order article via Infotrieve]
  10. Baxter G., Kenett, G., Blaney, F., and Blackburn, T. (1995) Trends Pharmacol. Sci. 16, 105-110 [CrossRef][Medline] [Order article via Infotrieve]
  11. Colas J.-F., Launay, J.-M., Kellermann, O., Rosay, P., and Maroteaux, L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5441-5445 [Abstract]
  12. Lauder J., M. (1993) Trends Neurosci. 16, 233-240 [CrossRef][Medline] [Order article via Infotrieve]
  13. Shuey, D. L., Sadler, T. W., and Lauder, J. M. (1992) Teratology 46, 367-378 [Medline] [Order article via Infotrieve]
  14. Huether, G., Rittner, I., Reimer, A., Adler, L., and Youdim, M. B. H. (1992) Biog. Amines 8, 421-430
  15. Yavarone, M. S., Shuey, D. L., Tamir, H., Sadler, T. W., and Lauder, J. M. (1993) Teratology 47, 573-584 [Medline] [Order article via Infotrieve]
  16. Choi, D.-S., Colas, J.-F., Kellermann, O., Launay, J.-M., Loric, S., Rosay, P., and Maroteaux, L. (1994) Cell. Mol. Biol. 40, 403-411
  17. Julius D., Livelli, T. J., Jessell, T. M., and Axel, R. (1989) Science 244, 1057-1062 [Medline] [Order article via Infotrieve]
  18. Julius, D., Huang, K. N., Livelli, T., Axel, R., and Jessell, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 928-932 [Abstract]
  19. Davis, R. J. (1993) J. Biol. Chem. 268, 14553-14556 [Free Full Text]
  20. Neer, E. J. (1995) Cell 80, 249-257 [Medline] [Order article via Infotrieve]
  21. Loric S., Maroteaux, L., Kellermann, O., and Launay, J.-M. (1995) Mol. Pharmacol. 47, 458-466 [Abstract]
  22. Berthou, L., Corvaia, N., Geffroy, C., Mutel, V., Launay, J.-M., and Alouf, J. E. (1992) Eur. J. Cell Biol. 58, 377-382 [Medline] [Order article via Infotrieve]
  23. Mc Pherson, G. A. (1985) J. Pharmacol. Methods 14, 213-228 [CrossRef][Medline] [Order article via Infotrieve]
  24. Siegel, S., and Castellan, N. J. J. (1988) Nonparametric Statistics for the Behavioral Sciences , McGraw Hill, New York
  25. Ganem, Y. J., Callebert, J., Darmon, M. C., Lasneret, J., Hosoda, S., Mallet, J., Launay, J.-M., and Dreux, C. (1989) Biog. Amines 6, 495-511
  26. Satoh, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5993-5997 [Abstract]
  27. Gupta, S. K., Gallego, C., Johnson, G. L., and Heasley, L. E. (1992) J. Biol. Chem. 267, 7987-7990 [Abstract/Free Full Text]
  28. Her, J. H. (1993) Biochem. J. 296, 25-31 [Medline] [Order article via Infotrieve]
  29. Fisher, J. M., Sossin, W., Newcomb, R., and Scheller, R. H. (1988) Cell 54, 813-822 [Medline] [Order article via Infotrieve]
  30. Maroteaux, L., Campanelli, J., and Scheller, R. H. (1988) J. Neurosci. 8, 2804-2815 [Abstract]
  31. Qiu, Y. H., and Davis, R. L. (1993) Genes & Dev. 7, 1447-1458
  32. Graham-Smith, D. (1972) The Carcinoid Syndrome , W. Heinemann, London
  33. Snell, K. C., and Stewart, H. L. (1969) Science 163, 470 [Medline] [Order article via Infotrieve]
  34. Hosoda, S., Nahamura, W., Snell, K. C., and Stewart, H. L. (1970) Science 170, 454-455 [Medline] [Order article via Infotrieve]
  35. Suyama, M., Saito, T., Hara, K., Kito, H., and Hosoda, S. (1984) J. Natl. Cancer Inst. 72, 751-757 [Medline] [Order article via Infotrieve]
  36. Conklin, B. R., and Bourne, H. R. (1993) Cell 73, 631-641 [Medline] [Order article via Infotrieve]
  37. Clapham, D. E., and Neer, E. J. (1993) Nature 365, 403-406 [CrossRef][Medline] [Order article via Infotrieve]
  38. Iniguez-Lluhi, J., Kleuss, C., and Gilman, A. G. (1993) Trends Cell Biol. 3, 230-236 [CrossRef]
  39. Inglese, J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 23735-23738 [Free Full Text]
  40. Xu N., McCormick, F., and Gutkind, J. S. (1994) Oncogene 9, 597-601 [Medline] [Order article via Infotrieve]
  41. Inglese, J., Koch, W. J., Touhara, K., and Lefkowitz, R. J. (1995) Trends Biochem. Sci. 20, 151-156 [CrossRef][Medline] [Order article via Infotrieve]
  42. Bourne, H. R. (1995) Nature 376, 727-729 [CrossRef][Medline] [Order article via Infotrieve]
  43. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302 [Medline] [Order article via Infotrieve]
  44. De Vivo, M., and Iyengar, R. (1994) J. Biol. Chem. 269, 19671-19674 [Abstract/Free Full Text]
  45. Rozengurt E. (1992) Curr. Opin. Cell Biol. 4, 161-165 [Medline] [Order article via Infotrieve]
  46. Alblas, J., vanCorven, E. J., Hordijk, P. L., Milligan, G., and Moolenaar, W. H. (1993) J. Biol. Chem. 268, 22235-22238 [Abstract/Free Full Text]
  47. Winitz, S., Russell, M., Qian, N. X., Gardner, A., Dwyer, L., and Johnson, G. L. (1993) J. Biol. Chem. 268, 19196-19199 [Abstract/Free Full Text]
  48. Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P., and Bernstein, K. E. (1995) Nature 375, 247-250 [CrossRef][Medline] [Order article via Infotrieve]
  49. Cook, S. J., Rubinfeld, B., Albert, I., and McCormick, F. (1993) EMBO J. 12, 3475-3485 [Abstract]
  50. Qian, N. X., Winitz, S., and Johnson, G. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4077-4081 [Abstract]
  51. Crespo, P., Xu, N., Simonds, W., and Gutkind, J. (1994) Nature 369, 418-420 [CrossRef][Medline] [Order article via Infotrieve]
  52. Faure, M., Voyno-Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854 [Abstract/Free Full Text]
  53. Marx, J. (1993) Science 262, 988-990 [Medline] [Order article via Infotrieve]
  54. Camps, M., Carozzi, A., Schnabel, P., Scheer, A., Parker, P. J., and Gierschik, P. (1992) Nature 360, 684-686 [CrossRef][Medline] [Order article via Infotrieve]
  55. Katz, A., Wu, D., and Simon, M. I. (1992) Nature 360, 686-689 [CrossRef][Medline] [Order article via Infotrieve]
  56. Pumiglia, K. M., LeVine, H., Haske, T., Habib, T., Jove, R., and Decker, S. J. (1995) J. Biol. Chem. 270, 14251-14256 [Abstract/Free Full Text]
  57. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mishak, H., Finkenzeller, G., Marmé, D., and Rapp, U. R. (1993) Nature 364, 249-252 [CrossRef][Medline] [Order article via Infotrieve]
  58. La Morte, V. J., Kennedy, E. D., Collins, L. R., Goldstein, D., Harootunian, A. T., Brown, J. H., and Feramisco, J. R. (1993) J. Biol. Chem. 268, 19411-19415 [Abstract/Free Full Text]
  59. La Morte, V. J., Thorburn, J., Absher, D., Spiegel, A., Brown, J. H., Chien, K. R., Feramisco, J. R., and Knowlton, K. U. (1994) J. Biol. Chem. 269, 13490-13496 [Abstract/Free Full Text]
  60. Mattingly, R. R., Sorisky, A., Brann, M. R., and Macara, I. G. (1994) Mol. Cell. Biol. 14, 7943-7952 [Abstract]
  61. Watanabe, T., Waga, I., Honda, Z., Kurokawa, K., and Shimizu, T. (1995) J. Biol. Chem. 270, 8984-8990 [Abstract/Free Full Text]
  62. Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654 [CrossRef][Medline] [Order article via Infotrieve]
  63. Barker, E., Westphal, R., Schmidt, D., and Sanders-Bush, E. (1994) J. Biol. Chem. 269, 11687-11690 [Abstract/Free Full Text]
  64. Kahan, C., Julius, D., Pouyssegur, J., and Seuwen, K. (1992) Exp. Cell Res. 200, 523-527 [Medline] [Order article via Infotrieve]
  65. Burstein, E. S., Spadling, T. A., Braüner-Osborne, H., and Brann, M. R. (1995) FEBS Lett. 363, 261-263 [CrossRef][Medline] [Order article via Infotrieve]
  66. Aragay, A. M., Collins, L. R., Post, G. R., Watson, A. J., Feramisco, J. R., Brown, J. H., and Simon, M. I. (1995) J. Biol. Chem. 270, 20073-20077 [Abstract/Free Full Text]
  67. Wu, D., Jiang, H., and Simon, M. I. (1995) J. Biol. Chem. 270, 9828-9832 [Abstract/Free Full Text]
  68. Kjelsberg, M. A., Cotecchia, S., Ostrowski, J., Caron, M. G., and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 1430-1433 [Abstract/Free Full Text]
  69. Morilak, D. A., and Ciaranello, R. D. (1993) Neuroscience 55, 869-880 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.